Kodiak Sciences Inc.(KOD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

KOD Kodiak Sciences Inc.

Market Closed 06-18 16:00:00 EDT

36.14

+0.43

+1.20%

盘后36.14

+0.000.00%

17:13 EDT

High37.50	Low35.18	Vol1.21M
Open36.80	D1 Closing35.71	Amplitude6.50%
Mkt Cap2.26B	Tradable Cap1.33B	Total Shares62.58M
T/O43.52M	T/O Rate3.27%	Tradable Shares36.88M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"KOD","market":"US","secType":"STK","nameCN":"Kodiak Sciences Inc.","latestPrice":36.14,"timestamp":1781812800000,"preClose":35.71,"halted":0,"volume":1205926,"hourTrading":{"tag":"盘后","latestPrice":36.14,"preClose":36.14,"latestTime":"17:13 EDT","volume":198025,"amount":7156618.972,"timestamp":1781817207032,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.012041444973396799,"floatShares":36879500,"shares":62578441,"eps":-4.157111,"marketStatus":"Market Closed","change":0.43,"latestTime":"06-18 16:00:00 EDT","open":36.8,"high":37.5,"low":35.18,"amount":43516822,"amplitude":0.064968,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.157111,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1782115200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1538625600000,"exchange":"NASDAQ","adjPreClose":35.71,"preHourTrading":{"tag":"盘前","latestPrice":36.8,"preClose":35.71,"latestTime":"09:29 EDT","volume":1477,"amount":54273.76815,"timestamp":1781789399999,"change":1.09,"changeRate":0.030524,"amplitude":0.021983},"postHourTrading":{"tag":"盘后","latestPrice":36.14,"preClose":36.14,"latestTime":"17:13 EDT","volume":198025,"amount":7156618.972,"timestamp":1781817207032,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.9857299658883885,"impliedVol":0.7877,"impliedVolPercentile":0.1594},"requestUrl":"/m/hq/s/KOD","defaultTab":"news","newsList":[{"id":"2641128453","title":"Kodiak Sciences CFO John A. Borgeson disposes of common shares worth $1.02 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2641128453","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641128453?lang=en_us&edition=fundamental","pubTime":"2026-06-06 05:57","pubTimestamp":1780696654,"startTime":"0","endTime":"0","summary":"Kodiak Sciences CFO John A. Borgeson sold 30,000 common shares on June 4, 2026, cutting his stake to 211,930 shares.The sales were priced at USD 34.01 for 25,896 shares, USD 34.67 for 4,104 shares.Borgeson also exercised a stock option for 30,000 shares at USD 1.04 on the same day.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kodiak Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nNDLcdYQDw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Kodiak Sciences CFO John A. Borgeson disposes of common shares worth $1.02 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","KOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641516082","title":"Kodiak Sciences shareholders elect Class II directors at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2641516082","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641516082?lang=en_us&edition=fundamental","pubTime":"2026-06-05 05:22","pubTimestamp":1780608163,"startTime":"0","endTime":"0","summary":"Kodiak Sciences held its annual shareholder meeting on June 2, 2026.Stockholders selected three directors to serve until the 2029 annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kodiak Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 04, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL7mhYqK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","KOD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639661102","title":"Kodiak Sciences CEO to present at Jefferies Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2639661102","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639661102?lang=en_us&edition=fundamental","pubTime":"2026-05-29 06:10","pubTimestamp":1780006228,"startTime":"0","endTime":"0","summary":"Kodiak Sciences will present at the Jefferies Global Healthcare Conference in New York on June 4, 2026, at 11:40 a.m. ET.Chief Executive Officer Victor Perlroth is scheduled to deliver the presentation.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDLS4Q2j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","KOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635822536","title":"Kodiak Sciences Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635822536","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635822536?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:35","pubTimestamp":1778621720,"startTime":"0","endTime":"0","summary":"Kodiak Sciences Inc reports results for the quarter ended March 31 - Earnings SummaryKodiak Sciences Inc KOD.OQ reported a quarterly adjusted loss of 94 cents per share for the quarter ended March 31,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL8N41P39K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","KOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634923618","title":"Kodiak Sciences upgraded to Buy from Neutral at Chardan","url":"https://stock-news.laohu8.com/highlight/detail?id=2634923618","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634923618?lang=en_us&edition=fundamental","pubTime":"2026-05-12 00:59","pubTimestamp":1778518786,"startTime":"0","endTime":"0","summary":"Chardan upgraded Kodiak Sciences (KOD) to Buy from Neutral with a $61 price target “Stellar results” from GLOW2, supported by enthusiasm among key ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kodiak-sciences-upgraded-to-buy-from-neutral-at-chardan-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kodiak-sciences-upgraded-to-buy-from-neutral-at-chardan-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KOD","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197948508","title":"Stock Track | Kodiak Sciences Soars 5.66% Intraday on Analyst Upgrade and Raised Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=1197948508","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197948508?lang=en_us&edition=fundamental","pubTime":"2026-05-11 21:35","pubTimestamp":1778506529,"startTime":"0","endTime":"0","summary":"Kodiak Sciences Inc. (KOD) saw its stock price soar 5.66% during intraday trading on Monday, following positive analyst actions.The surge comes after Chardan Capital upgraded the stock to Buy from...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["KOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634828174","title":"Chardan Upgrades Kodiak Sciences to Buy From Neutral, Raises Price Target to $61 From $14","url":"https://stock-news.laohu8.com/highlight/detail?id=2634828174","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634828174?lang=en_us&edition=fundamental","pubTime":"2026-05-11 20:54","pubTimestamp":1778504063,"startTime":"0","endTime":"0","summary":"Kodiak Sciences (KOD) has an average rating of buy and mean price target of $63.33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major bank","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4505","BK4139","KOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634899232","title":"Kodiak Sciences Raised to Buy From Neutral by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2634899232","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634899232?lang=en_us&edition=fundamental","pubTime":"2026-05-11 20:21","pubTimestamp":1778502060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KOD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 11, 2026 08:21 ET (12:21 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KOD","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634400274","title":"Analysts Offer Insights on Healthcare Companies: Kodiak Sciences (KOD), IN8bio (INAB) and Ultragenyx Pharmaceutical (RARE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634400274","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634400274?lang=en_us&edition=fundamental","pubTime":"2026-05-11 18:41","pubTimestamp":1778496084,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Kodiak Sciences (KOD), IN8bio (INAB) and Ultragenyx ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-kodiak-sciences-kod-in8bio-inab-and-ultragenyx-pharmaceutical-rare-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-kodiak-sciences-kod-in8bio-inab-and-ultragenyx-pharmaceutical-rare-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","LU0029874061.USD","BK4139","BK4581","RARE","INAB","XLV","BK4539","BK4588","BK4505","BK4137","LABU","XBI","LU0128526141.USD","BK4585","KOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633989450","title":"LifeSci Capital Remains a Buy on Kodiak Sciences (KOD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633989450","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633989450?lang=en_us&edition=fundamental","pubTime":"2026-05-08 22:56","pubTimestamp":1778252173,"startTime":"0","endTime":"0","summary":"In a report released today, Patrick Dolezal from LifeSci Capital maintained a Buy rating on Kodiak Sciences, with a price target of $65.00. Accordi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lifesci-capital-remains-a-buy-on-kodiak-sciences-kod-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lifesci-capital-remains-a-buy-on-kodiak-sciences-kod-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","KOD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633517106","title":"Kodiak Sciences Q1 EPS $(0.94) Misses $(0.92) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633517106","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633517106?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:25","pubTimestamp":1778185505,"startTime":"0","endTime":"0","summary":"Kodiak Sciences (NASDAQ:KOD) reported quarterly losses of $(0.94) per share which missed the analyst consensus estimate of $(0.92) by 2.17 percent. This is a 13.76 percent increase over losses of $(1.09) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52390820/kodiak-sciences-q1-eps-0-94-misses-0-92-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Kodiak Sciences Q1 EPS $(0.94) Misses $(0.92) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOD","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633175496","title":"Kodiak Sciences Q1 FY26 net loss widens to $58.2 million; R&D expenses rise to $48.5 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633175496","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633175496?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:00","pubTimestamp":1778184055,"startTime":"0","endTime":"0","summary":"Kodiak Sciences posted a first-quarter net loss of $58.2 million, or $0.94 per share, versus a loss of $57.5 million, or $1.09 per share, a year earlier.R&D expense climbed to $48.5 million from $43.6 million, driven by higher clinical activity in PEAK/PINNACLE and DAYBREAK studies.G&A expense fell to $11.2 million from $15.4 million, helped by sublease income from a corporate office building.Cash and cash equivalents totaled $169.5 million, with runway expected into 2027.Zenkuda posted positive Phase 3 GLOW2 topline results in diabetic retinopathy, with 62.5% achieving a ≥2-step DRSS improvement versus 3.3% for sham; DAYBREAK Phase 3 topline data in wet AMD expected September 2026, PEAK Phase 3 topline results in MESI expected in 4Q 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDLl90TY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOD","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633175440","title":"BRIEF-Kodiak Sciences Q1 Net Income USD -58.158 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633175440","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633175440?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:00","pubTimestamp":1778184046,"startTime":"0","endTime":"0","summary":"BRIEF-Kodiak Sciences Q1 Net Income USD -58.158 Million\n\n\nMay 07 (Reuters) - Kodiak Sciences Q1 operating expenses USD 59.777 million.\n\nQ1 operating income USD -59.777 million\nQ1 basic EPS USD -0.94\nQ1 EPS USD -0.94","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLXD18224:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","KOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633751251","title":"Kodiak Sciences Q1 Basic EPS USD -0.94","url":"https://stock-news.laohu8.com/highlight/detail?id=2633751251","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633751251?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:00","pubTimestamp":1778184002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLXD18224:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4139","KOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633175103","title":"Kodiak Sciences Q1 EPS USD -0.94","url":"https://stock-news.laohu8.com/highlight/detail?id=2633175103","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633175103?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:00","pubTimestamp":1778184002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLXD18224:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4505","KOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633195628","title":"Canaccord Genuity Reaffirms Their Buy Rating on Kodal Minerals (KOD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633195628","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633195628?lang=en_us&edition=fundamental","pubTime":"2026-05-07 12:15","pubTimestamp":1778127322,"startTime":"0","endTime":"0","summary":"Canaccord Genuity analyst Tim Huff reiterated a Buy rating on Kodal Minerals yesterday and set a price target of p1.00. According to TipRanks, Huff...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-reaffirms-their-buy-rating-on-kodal-minerals-kod-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-reaffirms-their-buy-rating-on-kodal-minerals-kod-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KOD","MTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633195097","title":"Will Positive Asian MESI Data and Phase 3 Expansion Reshape Kodiak Sciences' (KOD) Eye-Drug Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2633195097","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633195097?lang=en_us&edition=fundamental","pubTime":"2026-05-05 01:19","pubTimestamp":1777915142,"startTime":"0","endTime":"0","summary":"Kodiak Sciences has recently begun presenting new clinical and preclinical data for its bispecific eye therapy KSI-101 at the American Uveitis Society and ARVO 2026 meetings, including results from Phase 1b MESI cohorts in the U.S. and Asia that support continued global Phase 3 development.\nA key takeaway is that the Asian MESI cohort achieved visual gains consistent with U.S. APEX study outcomes, reinforcing the company’s multi-target bispecific and ABCD platform approach in inflammatory...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kod/kodiak-sciences/news/will-positive-asian-mesi-data-and-phase-3-expansion-reshape","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kod/kodiak-sciences/news/will-positive-asian-mesi-data-and-phase-3-expansion-reshape","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4505","KOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632569100","title":"Kodiak says Asian MESI cohort data support Phase 3 expansion of KSI-101 program","url":"https://stock-news.laohu8.com/highlight/detail?id=2632569100","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632569100?lang=en_us&edition=fundamental","pubTime":"2026-05-01 12:24","pubTimestamp":1777609445,"startTime":"0","endTime":"0","summary":"Kodiak Sciences scheduled new clinical updates on KSI-101 for macular edema secondary to inflammation at American Uveitis Society on May 2, 2026, with additional data slated for ARVO May 3-7, 2026.Results from tertiary-care uveitis patients were already generated, showing outcomes consistent with earlier U.S. Phase 1b APEX findings, supporting continued global development.First-time results from an Asian clinical cohort will be presented at ARVO, with patients showing meaningful vision and retinal anatomy improvements that were broadly consistent with U.S. experience.KSI-101 is being advanced in BLA-facing Phase 3 PEAK and PINNACLE studies, with topline readouts expected to begin in 4Q 2026.Company also plans to present preclinical work on bispecific inflammatory-disease candidates and multi-target geographic atrophy programs, positioning a broader pipeline beyond KSI-101.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDLbPSQg7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","KOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624538690","title":"J.P. Morgan Reaffirms Their Buy Rating on Kodiak Sciences (KOD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624538690","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624538690?lang=en_us&edition=fundamental","pubTime":"2026-04-04 20:21","pubTimestamp":1775305279,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Anupam Rama from J.P. Morgan maintained a Buy rating on Kodiak Sciences, with a price target of $60.00. According t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/j-p-morgan-reaffirms-their-buy-rating-on-kodiak-sciences-kod-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/j-p-morgan-reaffirms-their-buy-rating-on-kodiak-sciences-kod-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624434635","title":"Kodiak Sciences CFO John A. Borgeson disposes of common shares worth 1.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624434635","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624434635?lang=en_us&edition=fundamental","pubTime":"2026-04-03 08:27","pubTimestamp":1775176027,"startTime":"0","endTime":"0","summary":"Kodiak Sciences CFO John A. Borgeson exercised stock options for 30,000 shares at USD 1.04 on April 2, 2026.He sold 30,000 shares on April 2, 2026, at weighted-average prices ranging from USD 39.14 to USD 41.77.Directly held common shares totaled 183,316 following reported transactions.Stock options held totaled 58,614 following reported transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kodiak Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 02, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nNDLbsPb22:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Kodiak Sciences CFO John A. Borgeson disposes of common shares worth 1.2 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOD","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kodiak.com;ir.kodiak.com","stockEarnings":[{"period":"1week","weight":0.0639},{"period":"1month","weight":0.05},{"period":"3month","weight":0.6243},{"period":"6month","weight":0.39},{"period":"1year","weight":9.238},{"period":"ytd","weight":0.2926}],"compareEarnings":[{"period":"1week","weight":0.0122},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.1514},{"period":"6month","weight":0.0972},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.0951}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":-0.076525},{"month":2,"riseRate":0.5,"avgChangeRate":-0.093763},{"month":3,"riseRate":0.125,"avgChangeRate":-0.076889},{"month":4,"riseRate":0.625,"avgChangeRate":0.017136},{"month":5,"riseRate":0.5,"avgChangeRate":0.047406},{"month":6,"riseRate":0.625,"avgChangeRate":0.021672},{"month":7,"riseRate":0.571429,"avgChangeRate":0.078061},{"month":8,"riseRate":0.571429,"avgChangeRate":0.018756},{"month":9,"riseRate":0.714286,"avgChangeRate":0.127765},{"month":10,"riseRate":0.714286,"avgChangeRate":0.212883},{"month":11,"riseRate":0.75,"avgChangeRate":0.296496},{"month":12,"riseRate":0.625,"avgChangeRate":0.266402}],"exchange":"NASDAQ","name":"Kodiak Sciences Inc.","nameEN":"Kodiak Sciences Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kodiak Sciences Inc.(KOD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Kodiak Sciences Inc.(KOD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Kodiak Sciences Inc.,KOD,Kodiak Sciences Inc.股票,Kodiak Sciences Inc.股票老虎,Kodiak Sciences Inc.股票老虎国际,Kodiak Sciences Inc.行情,Kodiak Sciences Inc.股票行情,Kodiak Sciences Inc.股价,Kodiak Sciences Inc.股市,Kodiak Sciences Inc.股票价格,Kodiak Sciences Inc.股票交易,Kodiak Sciences Inc.股票购买,Kodiak Sciences Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kodiak Sciences Inc.(KOD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Kodiak Sciences Inc.(KOD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction